I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $361.55M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
A&G |
Columbia, Md. |
9/8/05 |
$2 |
New England Partners led the Series A financing, which included the Maryland Venture Fund and Crocker Capital |
Algeta ASA |
Oslo, Norway |
9/2/05 |
€23 (US$28.7) |
Participating in the Series A financing were new investors HealthCap, Advent Venture Partners and S.R. One and existing investors Selvaag Venture Capital, NorgesInvestor, Marlin Verdi AS and several smaller investors |
Amicus |
Cranbury, N.J. |
9/8/05 |
$55 |
Quaker BioVentures led the Series C financing and was joined by existing investors Canaan Partners, CHL Medical Partners, Frazier Healthcare Ventures, New Enterprise Associates, Prospect Venture Partners and Radius Ventures and new investors Palo Alto Investors and the GardenState Life Sciences Venture Fund |
Athenagen Inc. |
Menlo Park, Calif. |
9/19/05 |
$3.2 |
The Series A financing was led by Sanderling Ventures and included Life Science Angels; another $2.5M in milestone-driven investments could be earned within 12 months |
Bioheart Inc. |
Sunrise, Fla. |
9/27/05 |
$19 |
Participants in the Series D financing included Advent-Morro Equity Partners, The ASTRI Group, Magellan Group, Presidential Capital Partners, Dan Marino Investments, Minnesota Biomed Partners, New World Angels and the individuals William P. Murphy and David Gury |
Biolex |
Pittsboro, N.C. |
9/1/05 |
$36 |
The Series B financing was led by Polaris Venture Partners and included existing investors Intersouth Partners, Quaker BioVentures, Johnson & Johnson Development Corp., Mitsui and Co. Venture Partners and Kitty Hawk Capital |
BioLineRx |
Jerusalem |
9/26/05 |
$9 |
Existing investors Giza Venture Capital, Pitango Venture Capital and Teva Pharmaceuticals Industries Ltd. committed to follow-on investments |
Cellerant |
San Carlos, Calif. |
9/22/05 |
$9 |
Cellerant raised $9M in a second closing of its Series B round, bringing the total to $25M; in May it raised $16M in the first closing; participants in the second closing were Camelot Ventures, George Rathmann and Eminent Venture Capital Corp. |
Chiasma Inc. |
Jerusalem |
9/12/05 |
$6.2 |
The Series B financing was co-led by F-2 Ventures and the Ofer Hi-Tech Group; Series A investor InnoMed Fund and Yissum Ltd. also participated |
Dimerix |
Perth, Australia |
9/15/05 |
ND |
Foundation Capital led the Series A financing round, which included the Murdoch Westscheme Enterprise Partnership Fund; Startpharma Holdings Ltd. now owns 22 of Dimerix |
GlobeImmune |
Denver |
9/14/05 |
$34.3 |
The Series B round was led by Lilly Ventures and included other new investors Medica Holdings, Adams Street Partners, Biogen Idec Inc., Genentech Inc., Partners Healthcare and GC&H Investments and existing investors HealthCare Ventures LLC, Morgenthaler Ventures and Sequel Venture Partners |
Kereos Inc. |
St. Louis |
9/20/05 |
$19.5 |
New investors Prolog Ventures, Triathlon Medical Ventures and Charter Life Sciences, along with existing investor RiverVest Venture Partners, led the Series B round; also investing were Barnes-Jewish Hospital, Alafi Capital, Apjohn Ventures, Harris and Harris Group, Lux Capital, MB Venture Partners, Sigvion Capital, Vectis Life Science, Genentech Inc. and Royal Philips Electronics |
OncoMed |
Mountain View, Calif. |
9/7/05 |
$13.9 |
Investors in the Series A financing round included Latterell Venture Partners, U.S. Venture Partners, Morgenthaler Ventures and The Vertical Group |
PanGenetics |
Utrecht, the Netherlands |
9/8/05 |
$2 |
The seed financing round was led by Index Ventures |
Pervasis |
Cambridge, Mass. |
9/30/05 |
$12 |
The Series B financing round was led by new investor Highland Capital Partners and included founding investors Polaris Venture Partners and Flagship Venture Partners |
Replidyne |
Louisville, Colo. |
9/8/05 |
$62.5 |
The Series D financing was led by Duquesne Capital Management, Healthcare Investment Partners and MDS Life Sciences Technology II funds and included existing investors Health- Care Ventures, TPG Ventures, Morgenthaler Ventures, Perseus-Soros BioPharmaceutical Fund, Sequel Venture Partners, Temasek Holdings Pte. Ltd. and Quintiles Transnational; Aquilo Partners Inc. was placement agent |
Respirics Inc. |
Raleigh, N.C. |
9/27/05 |
ND |
Investors participating in the Series A financing included Catalysta Ventures and Research Triangle Ventures |
RioTech |
London |
9/12/05 |
£0.75 (US$1.35) |
Details on the financing round were not disclosed |
SpinX |
Geneva |
9/6/05 |
€10 (US$12.4) |
The Series B financing round was led by Bio Fund Management, with participation from existing investor Index Ventures, as well as from Auriga Partners, DFJ ePlanet Ventures and the CERN Pension Fund |
Teranode |
Seattle |
9/12/05 |
$9.5 |
The Series B round was led by Cargill Ventures and Trident Capital; Series A investors Ignition Partners and WRF Capital also participated |
Xigen SA |
Lausanne, Switzerland |
9/6/05 |
CHF21 (US$26) |
Investors in the Series A financing round were Tilocor Life Sciences, Venture Incubator and Initiative Capital |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $10M | ||||
Company |
Partner |
Amt. |
Triggering |
Details (Date) |
EpiCept |
Adolor Corp. |
ND |
Milestone payment |
Triggered by Adolor's initiation of a Phase II trial of a sterile lidocaine patch trademarked by EpiCept as LidoPAIN SP (9/26) |
Indevus |
Esprit Pharma Inc. |
$10 |
Milestone payment |
Triggered by initiation of the Phase III program for Sanctura XR in patients with overactive bladder (9/8) |
TransTech |
Novo Nordisk A/S (Denmark) |
ND |
Milestone payment |
Triggered by progress made with a drug candidate in their collaboration using TransTech's small- molecule discovery technology (9/22) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Private company. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.